Innovation
5 ways Johnson & Johnson is innovating in medicines and therapies
From rare diseases to all-too-common cancers, Johnson & Johnson is on a mission to improve treatment options for people around the globe. Learn more about how the company is working to create new therapies for IBD, lung cancer, major depressive disorder, bladder cancer, myasthenia gravis and more.
“Patients are the center of everything": Meet the scientist leader dedicated to developing effective IBD treatments
Her natural curiosity, determination and fascination with science inspired Esi Lamousé, M.D., Ph.D., to pursue a career that’s helped bring innovative therapies for inflammatory bowel disease to patients in need around the world.
How Johnson & Johnson is helping healthcare providers remotely monitor and support patient health
Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.
Could we be on our way to eliminating cancer for good?
What once seemed like an unattainable goal may soon be within our grasp. Learn how Johnson & Johnson is working toward its vision to create a world without cancer.
Featured stories
How Johnson & Johnson is advancing the fight against Alzheimer’s disease
After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.
Introducing the first and only daily disposable multifocal contact lens for people with astigmatism
A Johnson & Johnson scientist explains how the new Acuvue® Oasys Max 1-Day Multifocal for Astigmatism contact lens also filters blue light, supports the eye’s natural tear film and helps eyes easily switch focus from distance to reading.
Juvenile myasthenia gravis: Inside one adolescent’s journey
The condition is typically diagnosed in adults, but research suggests an uptick in adolescent patients. Learn more about the rare autoantibody disease, how one teen is managing it and why Johnson & Johnson is working to improve treatment options for patients of all ages.
Is this the end of one-size-fits-all treatments for depression?
Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
